GlassScriptPhysician profile
Jenn-Yu Jeff Lin
NPI 1821106493
$2,274.96
in general payments reported to CMS, 2019-2025
14 companies · $294 in 2025
The $294 reported for 2025 was more than what 84% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $379 · 2020: $216 · 2021: $426 · 2022: $311 · 2023: $376 · 2024: $274 · 2025: $294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $943.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $943.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $536.95 | 2022-2025 | Azstarys |
| Glaxosmithkline, LLC. | $533.34 | 2019-2025 | Bexsero, Pediarix, Rotarix |
| Kaleo, INC. | $245.51 | 2019-2024 | Auvi-Q |
| Tris Pharma INC | $193.27 | 2019-2025 | Dyanavel Xr, Onyda Xr |
| Pfizer INC. | $156.53 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $133.02 | 2021-2022 | |
| Sanofi Pasteur INC. | $105.76 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $105.46 | 2019-2025 | Vaxneuvance, Gardasil 9, Enflonsia |
| Sobi, INC | $92.85 | 2019 | |
| Ironshore Pharmaceuticals INC. | $80.33 | 2019 | |
| Supernus Pharmaceuticals, INC. | $42.06 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $24.79 | 2025 | |
| Novartis Pharmaceuticals Corporation | $13.96 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $11.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenn-Yu Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.